Target intelligence / Profile preview

Hemagglutinin stalk domain of group 1 Influenza A virus (HA stalk domain (group 1 IVA))

Target
HA stalk domain (group 1 IVA)
Molecular classification
Viral protein domain, Fusion protein domain, Attachment factor (component of class I viral fusion protein)
01

Overview

The hemagglutinin stalk domain of group 1 Influenza A viruses is a highly conserved region of the hemagglutinin surface glycoprotein, which is critical for mediating fusion between the viral envelope and host endosomal membranes during infection[1][2][3][4][6]. Unlike the immunodominant and variable HA head (receptor-binding) domain, the stalk (or stem) region evolves slowly, is intolerant to major sequence changes, and contains conserved epitopes recognized by broadly neutralizing antibodies, making it an attractive target for universal influenza vaccines and therapeutics[1][2][3]. HA is a homotrimeric protein, and the stalk region is composed mainly of the HA2 subunit, which undergoes a dramatic conformational rearrangement at low pH—triggering fusion of viral and host membranes[2][3][4]. Targeting the stalk domain is considered a promising approach for the development of broadly protective influenza interventions[1][2][3][6].

Other names
Influenza A hemagglutinin stem domain (group 1)HA stem domain (group 1)Group 1 Influenza A HA stalk
02

Mechanism of action

Inhibition of membrane fusion by preventing conformational change in the stalk domain Neutralization of viral entry into host cells

03

Biological functions

Viral fusion and entryMediating viral and endosomal membrane fusionTarget for broadly neutralizing antibodiesImmune response evasion
04

Disease associations

Infection (specifically in Influenza A virus infection)Target in influenza pandemic and seasonal outbreaks
05

Safety considerations

Potential for viral evolution and escape mutations under immune pressure, though such change in the stalk is rare due to its functional constraints[1][2]Risk for non-neutralizing antibody responses leading to antibody-dependent enhancement is theorized, but not established clinically
06

Interacting drugs

Broadly neutralizing antibodies specific to HA stalk (e.g., CR6261, FI6v3; these are in clinical/preclinical development and not traditional small molecules)

1 more in the full profile.

07

Biomarkers

Presence of anti-stalk domain antibodies (for monitoring universal influenza vaccine efficacy)

Beyond the preview

Go deeper on Hemagglutinin stalk domain of group 1 Influenza A virus (HA stalk domain (group 1 IVA)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hemagglutinin stalk domain of group 1 Influenza A virus (HA stalk domain (group 1 IVA)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call